Common use of CLINICAL INFORMATION Clause in Contracts

CLINICAL INFORMATION. i. Prescribed indications Treatment of severe heart rhythm disorder not responding to other therapies or when other treatments cannot be used. • Prior and post cardioversion • In patients who also have heart failure or left ventricular impairment Licensed indications • Tachyarrhythmias associated with ▇▇▇▇▇-▇▇▇▇▇▇▇▇▇-White syndrome. • Atrial flutter and fibrillation when other drugs cannot be used. • Tachyarrhythmias of paroxysmal nature including: supraventricular, nodal and ventricular tachycardias. Ventricular fibrillation; when other drugs cannot be used. Patients should NOT be on amiodarone for palpitation unless there is a clearly defined electrophysiological diagnosis. ii. Therapeutic summary Amiodarone is a class III antiarrhythmic drug (▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇ classification) that reduces the incidence of arrhythmias by increasing the duration and refractory period of the cardiac action potential prolonging the QT interval. It also slows heart rate and cardiac action potential conduction through inhibition of beta receptors and ion channels in a similar manner to antiarrhythmic drugs from classes IA, II and IV iii. Dose & Route of administration Oral loading* (by consultant/ specialist) 200mg 3 times daily for 1 week, reduced to 200mg twice daily for a further week. Maintenance Usually 200mg daily or the minimum dose required to control the arrhythmia. The minimum effective maintenance dose should be given because undesirable effects are usually dose related. Do not take with grapefruit juice.

CLINICAL INFORMATION. i. Prescribed indications Treatment of severe heart rhythm disorder not responding to other therapies or when other treatments cannot be used. •  Prior and post cardioversion •  In patients who also have heart failure or left ventricular impairment Licensed indications •  Tachyarrhythmias associated with ▇▇▇▇▇-▇▇▇▇▇▇▇▇▇-White syndrome. •  Atrial flutter and fibrillation when other drugs cannot be used. •  Tachyarrhythmias of paroxysmal nature including: supraventricular, nodal and ventricular tachycardias. Ventricular fibrillation; when other drugs cannot be used. Patients should NOT be on amiodarone for palpitation unless there is a clearly defined electrophysiological diagnosis. ii. Therapeutic summary Amiodarone is a class III antiarrhythmic drug (▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇ classification) that reduces the incidence of arrhythmias by increasing the duration and refractory period of the cardiac action potential prolonging the QT interval. It also slows heart rate and cardiac action potential conduction through inhibition of beta receptors and ion channels in a similar manner to antiarrhythmic drugs from classes IA, II and IV iii. Dose & Route of administration Oral loading* (by consultant/ specialist) 200mg 3 times daily for 1 week, reduced to 200mg twice daily for a further week. Maintenance Usually 200mg daily or the minimum dose required to control the arrhythmia. The minimum effective maintenance dose should be given because undesirable effects are usually dose related. Do not take with grapefruit juice.